The Access to COVID-19 Tools (ACT) Accelerator’s Country Readiness and Delivery (CRD) workstream, Project ECHO, Boost, TechNet-21, and the COVID-19 Vaccine Equity Project invite you to join a series of video-conference-based capacity building webinars.
Topic: Regulatory and Procurement Aspects for COVID-19 Vaccines
When: 9 March session (12-1PM CET)
Registration: https://echo.zoom.us/webinar/register/WN_60QBnRtURmaoXz2mGFWPIQ
TechNet-21 also manages two Telegram channels supporting regions, countries, and partners in preparing for COVID-19 vaccine introduction. In these two spaces - one anglophone and one francophone - you will be able to share your experiences, discuss key questions, and connect with experts from around the world. We'll also share new information and global guidance as it becomes available. Join us today:
COVID-19 Vaccine Introduction – TechNet-21 (English)
Introduction des vaccins contre la Covid-19 – TechNet-21 (Français)
Dear colleagues,
The recording of the webinar on Regulatory and Procurement Aspects for COVID-19 Vaccines is available in three languages here:
https://youtu.be/fY3vGBo9CQ0 (English)
https://youtu.be/0rGU1cSToX4 (Spanish)
https://youtu.be/TFHdx4j_fI8 (French)
Dear colleagues,
The questions that could not be answered during the webinar session have been compiled into the following Q&A document:
These are the questions that have been answered:
- Is there a link for the COVAX tracker?
- In Latin America, which countries have sent requests to the manufacturers for the test, because in PERU, it takes time, and it is not done yet.
- By not allowing or supporting testing by NRAs not creating a perception issue? If so, how is communication done to allay the anxiety in countries that may not be comfortable on this?
- Some NRAs have granted emergency use of the COVID-19 vaccines but continue to take samples of the vaccine in-country for testing. Are we saying NRAs shouldn't test all?
- Any list of the 48 PIP countries available?
- Are vaccines being approved for safety and quality by the manufacturing site (as is usual with usual medicines following Good Manufacturing Practice etc), or is the approval for emergency use and listing just by product? The concern is from partners at country level that different manufacturing sites (for the same product) will have different quality assurance mechanisms, and indeed for FCV countries may receive those which are sub-standard/ of poorer quality.
You can now find all the resources for all the COVID-19 Vaccine Introduction webinar sessions here: https://www.technet-21.org/en/topics/covid-19-vaccine
- Page :
- 1